Skip to main content

MoneyWorks4Me

Gland Pharma informs about appointment of chief investment officer

09 Nov 2026 Evaluate

Gland Pharma has informed that, Xiao Le has been appointed as the Chief Investment Officer of Gland Pharma International, (‘Gland Singapore’) the Wholly-owned subsidiary of the Company, effective November 09, 2026. Xiao Le will be responsible for exploring various investment opportunities and to improve M&A capability for Gland in the United States of America, China, Singapore and other countries. Xiao Le shall be reporting to the CEO of Gland Singapore. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are given in Annexure-A enclosed. 

The above information is a part of company’s filings submitted to BSE. 

Peers
Company Name CMP
Sun Pharma. Inds. 1908.45
Dr. Reddys Labs. 1385.20
Cipla 1421.45
Lupin 1996.00
Zydus Lifesciences 1199.90
View more..